Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in a related lung disease leading the drugmaker to expand the indications it ...
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...
Portal inflammation: mild to moderate. Staging for fibrosis Stage 1: zone 3 perivenular, peri-sinusoidal, or pericellular fibrosis; focal or extensive. Stage 2: as above, with focal or extensive ...
If you have diabetes, taking steps to manage it can help prevent related health issues, including MASH. Here’s what to know ...
Discover how integrating advanced imaging, digital pathology, and molecular analysis, can refine fibrosis staging and ...
Cystic fibrosis causes early-life changes in the immune system, leading to frequent inflammation that persists despite CFTR modulator therapies. These therapies improve mucus clearance but do not ...
Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback